Chronic lymphocytic leukemia presence impairs antigen-specific CD8
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
05
07
2022
accepted:
10
01
2023
revised:
22
12
2022
pubmed:
20
1
2023
medline:
10
3
2023
entrez:
19
1
2023
Statut:
ppublish
Résumé
T-cell dysregulation in chronic lymphocytic leukemia (CLL) associates with low response rates to autologous T cell-based therapies. How CLL affects antigen-specific T-cell responses remains largely unknown. We investigated (epi)genetic and functional consequences of antigen-specific T-cell responses in presence of CLL in vitro and in an adoptive-transfer murine model. Already at steady-state, antigen-experienced patient-derived T cells were skewed towards short-lived effector cells (SLEC) at the expense of memory-precursor effector cells (MPEC). Stimulation of these T cells in vitro showed rapid induction of effector genes and suppression of key memory transcription factors only in presence of CLL cells, indicating epigenetic regulation. This was investigated in vivo by following antigen-specific responses of naïve OT-I CD8
Identifiants
pubmed: 36658390
doi: 10.1038/s41375-023-01817-z
pii: 10.1038/s41375-023-01817-z
pmc: PMC9851097
doi:
Substances chimiques
Antigens
0
Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
606-616Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5:4054–8.
pubmed: 34478505
pmcid: 8945613
doi: 10.1182/bloodadvances.2021005083
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.
pubmed: 25317870
pmcid: 4267531
doi: 10.1056/NEJMoa1407222
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022;139:1794–806.
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563–71.
pubmed: 29713085
pmcid: 6117613
doi: 10.1038/s41591-018-0010-1
McLellan AD, Ali Hosseini Rad SM. Chimeric antigen receptor T cell persistence and memory cell formation. Immunol Cell Biol. 2019;97:664–74.
pubmed: 31009109
doi: 10.1111/imcb.12254
Man S, Henley P. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. Br J Haematol. 2019;186:220–33.
pubmed: 30945268
Peters FS, Strefford JC, Eldering E, Kater AP. T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica. 2021;106:1234–43.
pubmed: 33691381
pmcid: 8586819
doi: 10.3324/haematol.2020.267914
van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy. Blood. 2019;134:44–58.
pubmed: 31076448
pmcid: 7022375
doi: 10.1182/blood.2018885863
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612–21.
pubmed: 23247726
pmcid: 3587324
doi: 10.1182/blood-2012-09-457531
Görgün G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Investig. 2005;115:1797–805.
pubmed: 15965501
pmcid: 1150284
doi: 10.1172/JCI24176
Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002;99:6955–60.
pubmed: 12011454
pmcid: 124510
doi: 10.1073/pnas.102181599
Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T-cell receptor antagonist peptides induce positive selection. Cell. 1994;76:17–27.
pubmed: 8287475
doi: 10.1016/0092-8674(94)90169-4
Dekhtiarenko I, Ratts RB, Blatnik R, Lee LN, Fischer S, Borkner L, et al. Peptide processing is critical for T-cell memory inflation and may be optimized to improve immune protection by CMV-based vaccine vectors. PLoS Pathog. 2016;12:e1006072.
pubmed: 27977791
pmcid: 5158087
doi: 10.1371/journal.ppat.1006072
Lemmermann NA, Gergely K, Bohm V, Deegen P, Daubner T, Reddehase MJ. Immune evasion proteins of murine cytomegalovirus preferentially affect cell surface display of recently generated peptide presentation complexes. J Virol. 2010;84:1221–36.
pubmed: 19906905
doi: 10.1128/JVI.02087-09
Kavazovic I, Han H, Balzaretti G, Slinger E, Lemmermann NAW, Ten Brinke A, et al. Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity. PLoS Biol. 2020;18:e3000648.
pubmed: 32182234
pmcid: 7077837
doi: 10.1371/journal.pbio.3000648
Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods. 2017;14:959–62.
pubmed: 28846090
pmcid: 5623106
doi: 10.1038/nmeth.4396
Mackus WJ, Frakking FN, Grummels A, Gamadia LE, De Bree GJ, Hamann D, et al. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. Blood. 2003;102:1057–63.
pubmed: 12689926
doi: 10.1182/blood-2003-01-0182
Martin MD, Badovinac VP. Defining memory CD8 T cell. Front Immunol. 2018;9:2692.
pubmed: 30515169
pmcid: 6255921
doi: 10.3389/fimmu.2018.02692
Ataide MA, Komander K, Knopper K, Peters AE, Wu H, Eickhoff S, et al. BATF3 programs CD8(+) T cell memory. Nat Immunol. 2020;21:1397–407.
pubmed: 32989328
doi: 10.1038/s41590-020-0786-2
Hofland T, de Weerdt I, Endstra S, Jongejan A, Platenkamp L, Remmerswaal EBM, et al. Functional differences between EBV- and CMV-specific CD8(+) T cells demonstrate heterogeneity of T cell dysfunction in CLL. Hemasphere. 2020;4:e337.
pubmed: 32309780
pmcid: 7162091
doi: 10.1097/HS9.0000000000000337
Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Investig. 2008;118:2427–37.
pubmed: 18551193
pmcid: 2423865
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, et al. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model. Blood. 2015;126:212–21.
pubmed: 25979947
pmcid: 4497962
doi: 10.1182/blood-2015-02-626754
McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood. 2015;126:203–11.
pubmed: 25800048
pmcid: 4497961
doi: 10.1182/blood-2015-01-622936
Amsen D, Backer RA, Helbig C. Decisions on the road to memory. Adv Exp Med Biol. 2013;785:107–20.
pubmed: 23456843
doi: 10.1007/978-1-4614-6217-0_12
Mathieu C, Beltra JC, Charpentier T, Bourbonnais S, Di Santo JP, Lamarre A, et al. IL-2 and IL-15 regulate CD8+ memory T-cell differentiation but are dispensable for protective recall responses. Eur J Immunol. 2015;45:3324–38.
pubmed: 26426795
doi: 10.1002/eji.201546000
Takemoto N, Intlekofer AM, Northrup JT, Wherry EJ, Reiner SL. Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol. 2006;177:7515–9.
pubmed: 17114419
doi: 10.4049/jimmunol.177.11.7515
Llao Cid L, Hanna BS, Iskar M, Roessner PM, Ozturk S, Lichter P, et al. CD8(+) T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. Leuk Lymphoma. 2020;61:351–6.
pubmed: 31519123
doi: 10.1080/10428194.2019.1660972
Hudson WH, Gensheimer J, Hashimoto M, Wieland A, Valanparambil RM, Li P, et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+) stem-like CD8(+) T cells during chronic infection. Immunity. 2019;51:1043–58.e4.
pubmed: 31810882
pmcid: 6920571
doi: 10.1016/j.immuni.2019.11.002
Hanna BS, Llaó-Cid L, Iskar M, Roessner PM, Klett LC, Wong JKL, et al. Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity. Immunity. 2021;54:2825–41.e10.
pubmed: 34879221
doi: 10.1016/j.immuni.2021.11.004
Scott-Browne JP, López-Moyado IF, Trifari S, Wong V, Chavez L, Rao A, et al. Dynamic changes in chromatin accessibility occur in CD8+ T cells responding to viral infection. Immunity. 2016;45:1327–40.
pubmed: 27939672
pmcid: 5214519
doi: 10.1016/j.immuni.2016.10.028
Papavassiliou AG, Musti AM. The multifaceted output of c-Jun biological activity: focus at the junction of CD8 T cell activation and exhaustion. Cells. 2020;9:2470.
Zhou S, Cerny AM, Fitzgerald KA, Kurt-Jones EA, Finberg RW. Role of interferon regulatory factor 7 in T cell responses during acute lymphocytic choriomeningitis virus infection. J Virol. 2012;86:11254–65.
pubmed: 22875973
pmcid: 3457134
doi: 10.1128/JVI.00576-12
Masson F, Minnich M, Olshansky M, Bilic I, Mount AM, Kallies A, et al. Id2-mediated inhibition of E2A represses memory CD8+ T cell differentiation. J Immunol. 2013;190:4585–94.
pubmed: 23536629
pmcid: 3631715
doi: 10.4049/jimmunol.1300099
Raghu D, Xue HH, Mielke LA. Control of lymphocyte fate, infection, and tumor immunity by TCF-1. Trends Immunol. 2019;40:1149–62.
pubmed: 31734149
doi: 10.1016/j.it.2019.10.006
Jadhav RR, Im SJ, Hu B, Hashimoto M, Li P, Lin JX, et al. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proc Natl Acad Sci USA. 2019;116:14113–8.
pubmed: 31227606
pmcid: 6628832
doi: 10.1073/pnas.1903520116
Zhou X, Xue HH. Cutting edge: generation of memory precursors and functional memory CD8+ T cells depends on T cell factor-1 and lymphoid enhancer-binding factor-1. J Immunol. 2012;189:2722–6.
pubmed: 22875805
doi: 10.4049/jimmunol.1201150
Zhao X, Shan Q, Xue HH. TCF1 in T cell immunity: a broadened frontier. Nat Rev Immunol. 2022;22:147–57.
Zhong Y, Walker SK, Pritykin Y, Leslie CS, Rudensky AY, van der Veeken J. Hierarchical regulation of the resting and activated T cell epigenome by major transcription factor families. Nat Immunol. 2022;23:122–34.
pubmed: 34937932
doi: 10.1038/s41590-021-01086-x
Mellinghoff SC, Robrecht S, Mayer L, Weskamm LM, Dahlke C, Gruell H, et al. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia. 2022;36:562–5.
Itchaki G, Rokach L, Benjamini O, Bairey O, Sabag A, Vernitsky H, et al. Cellular immune responses to BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;138:638. Supplement 1
doi: 10.1182/blood-2021-150796
Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19:665–74.
pubmed: 31570879
pmcid: 7286441
doi: 10.1038/s41577-019-0221-9
Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am. 2013;27:173–206.
pubmed: 23561469
pmcid: 3660068
doi: 10.1016/j.hoc.2013.01.002
Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925–35.
pubmed: 7681471
doi: 10.1084/jem.177.4.925
Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27:281–95.
pubmed: 17723218
pmcid: 2034442
doi: 10.1016/j.immuni.2007.07.010
Yang CY, Best JA, Knell J, Yang E, Sheridan AD, Jesionek AK, et al. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol. 2011;12:1221–9.
pubmed: 22057289
doi: 10.1038/ni.2158
Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, et al. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol. 2011;12:1230–7.
pubmed: 22057288
pmcid: 3226770
doi: 10.1038/ni.2153
Chen GM, Chen C, Das RK, Gao P, Chen CH, Bandyopadhyay S, et al. Integrative bulk and single-cell profiling of premanufacture t-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 2021;11:2186–99.
pubmed: 33820778
pmcid: 8419030
doi: 10.1158/2159-8290.CD-20-1677
Luckey CJ, Bhattacharya D, Goldrath AW, Weissman IL, Benoist C, Mathis D. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci USA. 2006;103:3304–9.
pubmed: 16492737
pmcid: 1413911
doi: 10.1073/pnas.0511137103